Background: Prostate cancer (PCa) is one of the most frequently diagnosed tumors in men. In general, therapies for localized PCa are curative. However, treatment of advanced PCa is considered palliative since development of therapy resistance occurs rapidly. It has been shown that tumor-initiating cells are likely involved in therapy resistance. They are not eliminated by conventional therapies and thereby lead to tumor progression and relapse. The aim of this study was to evaluate the effects of the known stem cell inhibitor salinomycin on this critical subpopulation of cells.
| INTRODUCTION
Prostate cancer (PCa) is one of the most frequently diagnosed malignant tumors in men. Although therapy of localized PCa is curative, treatment of advanced PCa is considered palliative. Therapies for patients with biochemical and clinical recurrence predominantly target the androgen receptor (AR). However, these treatments inevitably lead to the development of castration-resistant PCa within a few years. A possible explanation for development of resistance to androgendirected therapies is the existence of cancer stem cells, which were described in detail by Maitland et al. 1 They postulate that there is a hierarchy within tumors and that the bulk population of tumor cells is derived from tumor-initiating cells, which represent a small selfrenewing subpopulation. 2 They may belong to the basal compartment of the prostate, 1 show no AR expression and thereby are not targeted by conventional therapies. 3 The issue of the origin of PCa is still open for discussion. Other researchers have described the role of prostate luminal progenitor cells in tumorigenesis. 4 However, there is still much discussion on how these aggressive cells can be identified and consequently targeted. Barrandon and Green 5 have described more than 30 years ago that single cells can form three morphologically different colony types with varying tumor-initiating potential: paraclones (low), meroclones (intermediate) and holoclones (high tumorinitiating potential). These distinct clonal colony types can be identified based on their morphology and marker expression 6 showed that holoclones display the highest tumorigenic potential when inoculated into mice, in contrast to paraclones.
The aim of this study was to analyze the effects of the stem cell inhibitor salinomycin, which has been described by Dewangan et al. 12 In particular, we determined the impact of salinomycin on the tumorinitiating CD24 − /CD44 high population. 13 Furthermore, we evaluated the effects of salinomycin on colony formation efficiency and distribution of colony types in docetaxel-sensitive and docetaxel-resistant cells using automated high-resolution colony formation analysis. Salinomycin has been used in docetaxel-resistant cells because those cells are known to express stem-like properties 14, 15 and the combination of salinomycin and docetaxel was earlier proposed to be a promising strategy to target both gastric cancer cells and cancer stem cells. 16 2 | MATERIALS AND METHODS 
| Cell culture

| High-resolution colony formation analysis
| Immunofluorescence staining
| Flow cytometry
| Statistical analysis
Statistical analysis was performed using GraphPad Prism 5 (Graph-Pad Software Inc., San Diego, CA). Differences between control and treatment groups were analyzed using the Student t test. P < .05 was considered statistically significant and encoded as follows: *P < .05; **P < .01. All experiments have been performed in at least three biological replicates.
| RESULTS
| Identification, characterization, and automated analysis of colony types in PCa cells
To investigate the three previously described colony types, 5 several PCa cell lines were seeded at low density and grown for 10 to 14 days. In general, the three colony types were found in all cell lines tested with the exception of PC3. Figure 1 shows representative images of the colony types with contrasting morphologies. Paraclones have a quite irregular structure with loosely packed cells that show the highest grade of differentiation. Holoclones, on the other hand, are tightly packed and very compact. Meroclones are semisolid, but they do not have the same dense structure as holoclones.
In this study, the classification of colony types was performed in an automated way using the software CATCH-colonies. In all cell lines, paraclones form the largest segment (from 56% in PC3 to 86% in LAPC4, Figure 2A ), followed by meroclones (from 10% in LAPC4 to 43% in PC3). Holoclones form the smallest part (from 0% in PC3 to 15% in DU145), which is in agreement with other publications. 7, 17 Figure 2B shows the clustering of the different colony types in Figure S1A ). Subsequently, we performed serial clonogenic assays to further confirm the correct annotation of the individual colony types. Paraclones showed the lowest colony formation efficiency in PC3 and DU145 cells and lost their proliferative potential after a few passages ( Figure 2C ). In contrast, meroclones and holoclones could be passaged over numerous rounds, which confirms their self-renewing potential. Of note, in PC3 cells did not give rise to classical holoclones with a dense inner core; however, meroclones in PC3 maintained a very high colony formation efficiency similar to holoclones in DU145 cells ( Figure 2C ). Subcultivation of single colonies predominantly led to the formation of daughter-colonies of their respective type ( Figure S1B ). Most importantly, only holoclones were able to give rise to all three types of colonies which has also been observed by others. 7 
| Salinomycin treatment reduces tumorinitiating CD24 − /CD44 high population
To validate the connection between identified colony types and the well-described tumor-initiating CD24 − /CD44 high cell population we performed immunofluorescence staining and fluorescence-activated cell sorting (FACS). Immunofluorescence staining revealed that holoclones in DU145 and meroclones in PC3 contain CD44positive cells that do not express CD24 ( Figure 3A 
| Salinomycin suppresses the formation of colonies with high tumor-initiating potential
| DISCUSSION
Despite the development of novel therapies for advanced PCa, the treatment options for castration-resistant PCa patients are still limited.
Many patients continue to progress after a short period of time and therapy resistance emerges quickly. 18 Hence, the treatment of advanced PCa remains a major issue and there is an urgent need to identify new therapeutic options to overcome therapy resistance. Common treatments for advanced stages of PCa include androgen deprivation therapy, inhibitors of androgen synthesis and anti-androgens such as enzalutamide and abiraterone. All these therapies target the AR in highly proliferative cells. Conventional therapies are inefficient in eliminating stem cells, which are AR-negative 3 and only show low proliferation and apoptosis rates. 19 Therefore, it is important to find novel treatment options that eliminate the small population of tumor-initiating cells that represent the top of the hierarchy in the bulk of PCa cells.
There is still much discussion on how tumor-initiating PCa cells can be identified and many approaches already exist. In this study, the classification of colony types was performed automatically by the CATCH-colonies software, which eliminates subjective staining that holoclones represent the tumor-initiating CD24 − /CD44 high population that has previously been described by Al-Hajj et al. 13 The therapeutic compound salinomycin is an antibacterial drug that is naturally produced by Streptomyces albus and has previously been used as coccidiostat in animals. 20 The mechanism of action is still not fully elucidated and numerous pathways have been described to be targeted by salinomycin. 12 Salinomycin has been reported to exert anticancer effects in several tumor entities including PCa. [21] [22] [23] [24] In detail, it has been shown that gastric cancer stem cells, which were characterized by enhanced Wnt/β-catenin signaling, are targeted by salinomycin supporting its activity against tumor-initiating cells. 25 Moreover, it was demonstrated that salinomycin also decreased the CD24 − /CD44 + stem-like population in breast cancer cells 26 
and
Fuchs et al 27 observed that salinomycin overcomes apoptosis resistance in human cancer cells. As evidenced in chemoradioresistant nasopharyngeal cancer, salinomycin may inhibit the expression of Nanog protein, in concordance with the results reported in the present study. 28 It has been reported that salinomycin entered clinical trials 29 ; however, no outcome of these studies was reported yet. F I G U R E 4 Salinomycin decreases colony formation efficiency by targeting tumor-initiating clones. A, Colony formation efficiency of PC3, PC3-DR, DU145, and DU145-DR treated with the indicated concentrations of salinomycin was assessed by determining colony numbers after 10 days. Quantification was performed by the CATCH-colonies software. Data represent mean ± SEM (*P < .05; **P < .01; t test). B, Clustering of colony types in PC3 treated with the indicated concentrations of salinomycin (paraclones, red; meroclones, blue). C, Relative number of each colony type in PC3 and PC3-DR upon salinomycin treatment was analyzed by the software CATCH-colonies. Values indicated are mean ± SEM (*P < .05; t test). D, Clustering of colony types in DU145 upon salinomycin treatment (paraclones, red; meroclones, blue; holoclones, green). E, Relative number of each colony type in DU145 and DU145-DR upon salinomycin treatment. Data represent mean ± SEM (*P < .05; **P < .01; t test) [Color figure can be viewed at wileyonlinelibrary.com]
